A monoclonal anti-thromboxane B2 antibody

Area of Science:

• Biochemistry
• Immunology
• Analytical Chemistry

Background:

• Thromboxane B2 (TXB2) is a key metabolite in cardiovascular and inflammatory pathways.
• Accurate quantification of TXB2 is crucial for understanding various physiological and pathological processes.
• Development of specific and sensitive assays for TXB2 is an ongoing area of research.

Purpose of the Study:

• To describe a novel monoclonal antibody against thromboxane B2.
• To evaluate the antibody's performance in radioimmunoassays.
• To assess the antibody's suitability for measuring TXB2 in biological samples.

Main Methods:

• Development of a monoclonal antibody against thromboxane B2.
• Characterization of the antibody's binding affinity and detection limit using radioimmunoassays.
• Assessment of cross-reactivity with structurally related compounds and other prostaglandins.
• Validation of the antibody for TXB2 measurement in tissue culture supernatants and human serum.

Main Results:

• The monoclonal antibody exhibits a detection limit of approximately 40 pg and a binding affinity of 1.98 x 10(9) M-1.
• Limited cross-reactivity was observed with closely related thromboxane B2 analogs (e.g., 2,3-dinor-TXB2, TXB1, TXB3).
• No significant cross-reactivity was detected with other prostaglandins or prostacyclin metabolites.
• The antibody demonstrated suitability for quantifying TXB2 in both tissue culture supernatants and human serum.

Conclusions:

• A highly specific and sensitive monoclonal antibody against thromboxane B2 has been developed.
• This antibody is well-suited for standard fluid phase radioimmunoassays.
• The antibody enables reliable measurement of thromboxane B2 levels in complex biological matrices.